The online version of this article (https://doi.org/10.1007/s12325-019-00998-3) contains supplementary material, which is available to authorized users.
To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.8131589.
A systematic literature review was conducted to review and summarize the economic impact of non-medical switching (NMS) from biologic originators to their biosimilars (i.e., switching a patient’s medication for reasons irrelevant to the patient’s health).
English publications reporting healthcare resource utilization (HRU) or costs associated with biosimilar NMS were searched in PubMed and EMBASE over the past 10 years and from selected scientific conferences over the past 3 years, along with gray literature for all biologics with an approved biosimilar (e.g., tumor-necrosis factor inhibitors, erythropoiesis-stimulating agents, insulin and hormone therapies).
A total of 1311 publications were retrieved, where 54 studies met the selection criteria. Seventeen studies reported increased real-world HRU or costs related to biosimilar NMS, e.g., higher rates of surgery (11%), steroid use (13%) and biosimilar dose escalating (6–35.4%). Among the studies that the estimated cost impact associated with NMS, 33 reported drug costs reduction, 12 reported healthcare costs post-NMS without a detailed breakdown, and 5 reported NMS setup and managing costs. Cost estimation/simulation studies demonstrated the cost reduction associated with NMS. However, variation across studies was substantial because of heterogeneity in study designs and assumptions (e.g., disease areas, scenarios of drug price discount rates, cost components, population size, study period, etc.).
Real-world studies reporting the economic impact of biosimilar NMS separately from drug costs are emerging, and those that reported such results found increased HRU in patients with biosimilar NMS. Studies of cost estimation have been largely limited to drug prices. Comprehensive evaluation of the economic impact of NMS should incorporate all important elements of healthcare service needs such as drug price, biologic rebates, HRU, NMS program setup, administration and monitoring costs.
Supplementary material 1 (DOCX 17 kb)12325_2019_998_MOESM1_ESM.docx
US Pharmacist. The use of biologics in cancer therapy. https://www.uspharmacist.com/article/the-use-of-biologics-in-cancer-therapy. 2010. Accessed Dec 7 2018.
Morrow T, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthc. 2004;1(4):24–9.
Declerck P, Danesi R, Petersel D, Jacobs I. The language of biosimilars: clarification, definitions, and regulatory aspects. Drugs. 2017;77(6):671–7.
Bridges SL Jr, White DW, Worthing AB, Gravallese EM, O’Dell JR, Nola K, et al. The science behind biosimilars: entering a new era of biologic therapy. Arthritis Rheumatol. 2018;70(3):334–44.
Generics and Biosimilars Initiative (GaBI). Biosimilars approved in Europe. http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe. 2017. Accessed Dec 7 2018.
Grabowski H, Guha R, Salgado M. Biosimilar competition: lessons from Europe. Nat Rev Drug Discov. 2014;13:99.
Mehr SR, Brook RA. Factors influencing the economics of biosimilars in the US. J Med Econ. 2017;20(12):1268–71.
FiercePharma. Targeting a $5B brand, Samsung and Merck launch Remicade biosimilar at 35% discount. https://www.fiercepharma.com/pharma/samsung-merck-launch-remicade-biosim-at-35-discount. 2017. Accessed Dec 7 2018.
Posner J, Griffin JP. Generic substitution. Br J Clin Pharmacol. 2011;72(5):731–2.
Liberman JN, Roebuck MC. Prescription drug costs and the generic dispensing ratio. J Manag Care Pharm. 2010;16(7):502–6.
Grabowski HG, Guha R, Salgado M. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future. Health Aff (Millwood). 2014;33(6):1048–57.
Singh SC, Bagnato KM. The economic implications of biosimilars. Am J Manag Care. 2015;21(16 Suppl):s331–40.
Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463–78.
The Biosimilars Council. Biosimilars in the United States. http://biosimilarscouncil.org/wp-content/uploads/2019/03/Biosimilars-Council-Patient-Access-Study.pdf. 2017. Accessed Dec 7 2018.
Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Ottawa: The Ottawa Health Research Institute; 2011.
Glintborg B, Sørensen J, Hetland ML. THU0648 use of outpatient rheumatologic health care services before and after switch from originator to biosimilar infliximab. Ann Rheum Dis. 2017;76(Suppl 2):450–1.
Glintborg B, Sørensen J, Hetland ML. Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis. RMD Open. 2018;4(2):e000710.
Phillips K, Juday T, Zhang Q, Keshishian A. SAT0172 economic outcomes, treatment patterns, and adverse events and reactions for patients prescribed infliximab or ct-p13 in the turkish population). Ann Rheum Dis. 2017;76(Suppl 2):835.
Szlumper C, Topping K, Blackler L, Kirkham B, Ng N, Cope A, et al. Switching to biosimilar etanercept in clinical practice. Rheumatology. 2017;56(suppl_2):139.
Peral C, Valderrama M, Montoro M, Gomez S, Tarallo M. Cost methods including CE/CB/CU, resource use, productivity, valuation and health econometrics (CS). Barcelona: ISPOR; 2018.
Shah K, Flora K, Penn H. Cost effectiveness of a high intensity programme (HIP) compared to a low intensity programme (LIP) for switching patients with rheumatoid arthritis to the etanercept biosimilar. Rheumatology. 2018;57(suppl_3):075.
Zahorian T, Farraye F, Reich J, Noronha A, Wasan S, Shah B. Successful transition to an infliximab biosimilar at an Academic Hospital. Philadelphia: American College of Gastroenterology; 2018.
Barnes T, Wong E, Thakrar K, Douglas K, Glen F, Young-Min S, et al. 106 Switching stable rheumatology patients from an originator biologic to a biosimilar: resource cost in the UK. Rheumatology. 2018;57(suppl_3):075.
Flodmark CE, Lilja K, Woehling H, Jarvholm K. Switching from originator to biosimilar human growth hormone using dialogue teamwork: single-center experience from Sweden. Biol Ther. 2013;3:35–43.
Peck R. Peripheral blood stem cell mobilisation: an experience of switching to biosimilar G-CSF. 2017; Glasgow.
Rodríguez JR. 5PSQ-084 Safety and effectiveness of switching to infliximab biosimilar in digestive and rheumatological pathology. Eur J Hosp Pharm. 2018;25(Suppl 1):A203–4.
Nisar MK. 292 Switching to biosimilar rituximab: a real world study. Rheumatology. 2018;57(suppl_3):075.
Rodríguez Glez G, Díaz Hernández L, Morales Barrios J, Vela González M, Tardillo Marín C, Viña Romero M, et al. P629 Efficacy, safety and economic impact of the switch to biosimilar of infliximab in inflammatory bowel disease patients in clinical practice: results of one year. J Crohn’s Colitis. 2017;11(suppl_1):S402.
Plevris N, Deekae A, Jones GR, Manship TA, Noble CL, Satsangi J, et al. A novel approach to the implementation of biosimilar infliximab CT-P13 for the treatment of IBD utilising therapeutic drug monitoring: the Edinburgh Experience. Gastroenterology. 2017;152(5):S385.
Minutolo R, Borzumati M, Sposini S, Abaterusso C, Carraro G, Santoboni A, et al. Dosing penalty of erythropoiesis-stimulating agents after switching from originator to biosimilar preparations in stable hemodialysis patients. Am J Kidney Dis. 2016;68(1):170–2.
Clair Jones A, Smith M. P527 Infliximab biosimilar switching program overseen by specialist pharmacist saves money, realises investment and optimises therapy. J Crohn’s Colitis. 2017;11(suppl_1):S348.
Ratnakumaran R, To N, Gracie DJ, Selinger CP, O’Connor A, Clark T, et al. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Scand J Gastroenterol. 2018;53(6):700–7.
Gutermann L, Apparuit M, Boissinot L, Bruneau A, Zerhouni L, Conort O, et al. CP-150 Evaluation of infliximab (remicade) substitution by infliximab biosimilar (inflectra): cost savings and therapeutic maintenance. Eur J Hosp Pharm. 2017;24(Suppl 1):A67–8.
Sheppard M, Hadavi S, Hayes F, Kent J, Dasgupta B. AB0322 preliminary data on the introduction of the infliximab biosimilar (CT-P13) to a real world cohort of rheumatology patients. Ann Rheum Dis. 2016;75(Suppl 2):1011.
Razanskaite V, Bettey M, Downey L, Wright J, Callaghan J, Rush M, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11(6):690–6.
Dyball S, Hoskins V, Christy-Kilner S, Haque S. Effectiveness and tolerability of benepali in rheumatoid arthritis patients switched from Enbrel. Hoboken: Wiley; 2017.
Valido A, Silva-Dinis J, Saavedra MJ, Bernardo N, Fonseca JE. AB1231 Efficacy and cost analysis of a systematic switch from originator infliximab to biossimilar ct-p13 of all patients with inflammatory arthritis from a single centre. Ann Rheum Dis. 2018;77(Suppl 2):1712–3.
Barnes T, Wong E, Thakrar K, Glen F, Young-Min S, Marchbank K, et al. The resource cost of switching stable rheumatology patients from an originator biologic to a biosimilar in the UK. Value Health. 2017;15:60.
Gibofsky A, Garg V, Yang M, Qi C, Skup M. AB0416 Estimating the short-term costs associated with non-medical switching in rheumatic diseases. London: BMJ Publishing Group Ltd; 2018.
Brown C, McCann E. Cost of switching from an originator biologic (Remicade) to a biosimilar. Value Health. 2016;19(7):A581.
Gibofsky A, Skup M, Yang M, Mittal M, Macaulay D, Ganguli A. Short-term costs associated with non-medical switching in autoimmune conditions. Clin Exp Rheumatol. 2018;37:97.
Husereau D, Feagan B, Selya-Hammer C. Policy options for infliximab biosimilars in inflammatory bowel disease given emerging evidence for switching. Appl Health Econ Health Policy. 2018;16(3):279–88.
Hakim A, Ross JS. Obstacles to the adoption of biosimilars for chronic diseases. JAMA. 2017;317(21):2163–4.
FDA. Purple book: Lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations. https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/ucm411418.htm. 2018. Accessed Dec 7 2018.
Lakatos P. European experience of infliximab biosimilars for the treatment of inflammatory bowel disease. Gastroenterol Hepatol. 2016;12(2):119–21.
Jha A, Dunlop W, Upton A. Budget impact analysis of introducing biosimilar infliximab for the treatment of gastro intestinal disorders in five European Countries. Oxford: Oxford University Press; 2015.
Jha A, Upton A, Dunlop WC, Akehurst R. The budget impact of biosimilar infliximab (Remsima(R)) for the treatment of autoimmune diseases in five European Countries. Adv Ther. 2015;32(8):742–56.
Ala K, Avery P, Wilson R, Prowse A, Shutt J, Jupp J, et al. PTU-059 early experience with biosimilar infliximab at a district general hospital for an entire Crohn’s disease patient cohort switch from remicade to inflectra. Gut. 2016;65(Suppl 1):A81.
Becciolini A, Psachoulia E, Biggioggero M, Crotti C, Agape E, Negrini C, et al. The introduction of etanercept biosimilar in the practice of a tertiary rheumatologic Centre in Italy: a budget impact model. Value Health. 2016;19(7):A534.
Bhattacharyya S, Banerjee S, Clinton H, Faithfull G, Mendoza C. Impact of etanercept biosimilar launches on healthcare spending: a UK budget impact model for the treatment of rheumatoid arthritis and chronic plaque psoriasis. Value Health. 2016;19(7):A580–1.
Bocquet F, Fusier I, Cordonnier A, Lechat P, Paubel P. Marketing of the first biosimilar infliximab in France: what budgetary impact in the public hospitals of Paris? Presented at the Société Française de Pharmacologie et de Thérapeutique (SFPT) meeting, April 2016. http://pharmacie-hospitaliere-ageps.aphp.fr/marketing-biosimilar-infliximab-france-budgetary-impact-public-hospitals-paris/. 2016. Accessed Dec 7 2018.
Rahmany S, Cotton S, Garnish S, McCabe L, Brown M, Saich R, et al. PTH-157 The introduction of biosimilar infliximab (CT-P13) through a managed switching programme generates significant cost savings with high levels of patient satisfaction. Gut. 2016;65(Suppl 1):297.
Shah A, Mwamburi M. Modeling the budget impact of availability of biosimilars of infliximab and adalimumab for treatment for rheumatoid arthritis using published claim-based algorithm data in the United States. Value Health. 2016;19(3):A228.
Trancart M, Lafuma A, Laurendeau C. Budget impact of etanercept biosimilars in the treatment of rheumatoid arthrisis: an analysis based on French National Claims Database. Value Health. 2016;19(7):A532–3.
Alexandre R, Squiassi H, Santana C. Cost minimization analysis in the switch of infliximab for its biosimilar in the Brazilian private healthcare system. Presented at the ISPOR 22nd Annual International Meeting (poster PMS37). 2017.
Gómez GC, Nicolás FG, Eguilior NY, Casariego GN, Romero MV, Molina MB, et al. CP-182 Potential economical impact of biosimilar adalimumab. Eur J Hosp Pharm. 2017;24(Suppl 1):A81–2.
Szlumper C, Laftah Z, Smith C, Barker J, Mercer S, Benton E, et al. Switching to biosimilar etanercept in clinical practice: a prospective cohort study. Br J Dermatol. 2017;177:62.
García-Fernandez C, Ruiz-Fuentes S, Belda-Rustarazo S, Gómez-Peña C, Morón-Romero R, Gómez-Nieto P. 2SPD-013 Economic impact of biosimilar infliximab use. Eur J Hosp Pharm. 2018;25(Suppl 1):A15.
Healy M, Crook J, Chavda C, Smith E. P35 An experience of switching paediatric inflammatory bowel disease patients on infliximab therapy to the biosimilar ‘remsima’. Arch Dis Child. 2018;103(2):e1.
Ma J, Petford S, Jones L, Douglas K, John H. Audit of the clinical efficacy and safety of etanercept biosimilar to its reference product in patients with inflammatory arthritis: experience from a district general hospital in the United Kingdom. Rheumatology. 2018;57(suppl_3):075.
Mora AM, Rosa VG, Torres MS. 1ISG-008 Economic impact of the use of biosimilar infliximab in a second-level hospital. Eur J Hosp Pharm. 2018;25(Suppl 1):A4.
O’Brien G, Carrol D, Walshe V, Mulcahy M, Courtney G, Omahony C, et al. A cost saving measure from the utilisation of biosimilar infliximab in the Irish secondary care setting. Barcelona: ISPOR; 2018.
Shah K, Flora K, Penn H. 232 Clinical outcomes of a multi-disciplinary switching programme to biosimilar etanercept for patients with rheumatoid arthritis. Rheumatology. 2018;57(suppl_3):075.
Abraham I, Han L, Sun D, MacDonald K, Aapro M. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. Future Oncol. 2014;10(9):1599–609.
Sun D, Andayani TM, Altyar A, MacDonald K, Abraham I. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study. Clin Ther. 2015;37(4):842–57.
McBride A, Abraham I, MacDonald K, Campbell K, Bikkina M, Balu S. Cost savings of conversion from filgrastim or pegfilgrastim to biosimilar filgrastim-sndz for chemotherapy-induced (febrile) neutropenia (CIN/FN) prophylaxis and expanded access to biosimilar GCSF on a budget neutral basis. J Clin Oncol. 2017;35(15_suppl):e18334.
McBride A, Campbell K, Bikkina M, MacDonald K, Abraham I, Balu S. Expanded access to obinutuzumab from cost-savings generated by biosimilar filgrastim-sndz in the prophylaxis of chemotherapy-induced (febrile) neutropenia: US simulation study. Blood. 2017;130(Suppl 1):3380.
McBride A, Balu S, Campbell K, Bikkina M, MacDonald K, Abraham I. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. Future Oncol. 2017;13(25):2285–95.
Ravonimbola H, Petrica N, Maurel F, Murphy C, Doré C, Fresneau L. A cost-effectiveness analysis comparing the originator recombinant human alfa to their biosimilars follitropin alfa for the treatment of infertility. Value Health. 2017;20(9):A522.
Claus B, Simoens S, Vanhorebeek S, Commeyne S. Budget impact analysis of the introduction of biosimilars in a Belgian Tertiary Care Hospital: a simulation. Value Health. 2016;19(7):A460.
Reichardt B, Reiter G, Stamm T, Nell-Duxneuner V. THU0770-HPR Cost savings by favouring infliximab biosimilars in the eastern region of austria. Ann Rheum Dis. 2017;76:1494.
- Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review
Eric Q. Wu
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Sommerakademie-Visual, Mail Icon II